Halozyme Therapeutics, Inc. vs. Repligen Corp
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| HALO | RGEN | |
|---|---|---|
| Market Cap | $12.45 billion | $9.48 billion |
| Revenue (TTM) | $1.66 billion | $785.10 million |
| Net Income (TTM) | $413.60 million | $41.54 million |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | RGEN | |
|---|---|---|
| P/E Ratio | 32.63 | 239.36 |
| Price / Book | 86.72 | 4.49 |
| Price / Sales | 7.48 | 12.08 |
HALO leads on 2 of 3 valuation factors.
Profitability
| HALO | RGEN | |
|---|---|---|
| Net Margin | 24.86% | 5.29% |
| Return on Equity | 288.13% | 1.97% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| HALO | RGEN | |
|---|---|---|
| Short Interest | 9.79% | 7.13% |
RGEN leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, RGEN overview, RGEN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.